Many studies estimate that 20% of people are infected by human papillomavirus (HPV) worldwide, and 500.000 new cases of cervical carcinoma appear yearly, 70% in developing countries, almost all associated to this virus, as so several cases of anal carcinoma. These data indicate the necessity of reinforced screening for anogenital carcinomas and their precursors, and vaccines offer this opportunity. Nowadays, there is vaccination against viral types 16/18, the most associated to neoplasia, and 6/11 that provoke condylomas. Vaccines are indicated to women among 11 and 25 years old since they did not have previous contact with HPV. Vaccines induce immunization superior to that naturally acquired, although, its duration period is not well established. They are not yet indicated to males. Vaccination does not exclude necessity for periodical screening tests for anogenital cancer.
Papillomavirus infections; Intra-epithelial neoplasia; prevention and control; Papillomavirus, vaccine; Carcinoma, squamous cell